| abstract |
The present invention relates to crystalline forms of the PD-1/PD-L1 inhibitor (n R )-1-((7-cyano-2-(3'-(3-(((n R )-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, and related synthetic intermediates, where the compound is useful in the treatment of various diseases including infectious diseases and cancer. |